- Chung, H. C., Bang, Y., Fuchs, C. S., Qin, S., Satoh, T., Shitara, K., Tabernero, J., et al. (2020). KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction cancer (mG/GEJc): A double-blind, randomized, placebo-controlled phase III study. Journal of Clinical Oncology, 38(4)
KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction cancer (mG/GEJc): A double-blind, randomized, placebo-controlled phase III study
on 15 de juny de 2020
with No hi ha comentaris
Deixa un comentari